Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ultragenyx Pharma (RARE) PT Lowered to $66 at Citi
August 5, 2019 6:26 AM EDTCiti analyst Yigal Nochomovitz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $66.00 (from $69.00) while maintaining a Neutral rating.
... MoreUltragenyx Pharma (RARE) Misses Q2 EPS by 2c, Revenues Beat
August 1, 2019 5:39 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.02 worse than the analyst estimate of ($1.70). Revenue for the quarter came in at $24.15 million versus the consensus estimate of $22.52 million.
The U.S. launch of Crysvita continues to be strong with the number of patients on reimbursed... More
